Evaluate Recovery of Testosterone for Patients Using Eligard

Prostate Cancer Clinical Trial

— Eligard  

Official title:

A 12 Month Open Label Study of Serum Testosterone Recovery and PSA After Neo-Adjuvant Treatment With Eligard(TM) 22.5mg Used With Radiation Therapy in Patients With Early Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01136226
• Other study ID #: CURA-RT-001
• Status: Completed
• Phase: Phase 4
• Start date: October 2003
• Est. completion date: June 2009

Study information

• Verified date: September 2018
• Source: Chesapeake Urology Research Associates
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if testosterone will recover to 90% by year 1 after using Eligard.

Description:

This is a Multi-center, open-label study to evaluate testosterone recovery after six months of neo-adjuvant treatment with ELIGARD (TM) 22.5mg used with Radiation Therapy in patients with TNM T1, T2 or T3A adenocarcinoma of the prostate. The 60 patients will receive two subcutaneous administration of ELIGARD (TM) 22.5mg (Baseline and Month 3) and receive Radiation Therapy (Month 2-4).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: June 2009
• Est. primary completion date: June 2009
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 50 Years to 80 Years

Eligibility

Inclusion Criteria:

• Must be outpatient, not hospitalized

• Male Patient between ages 50-80, inclusive

• Histologically/Cytologically graded adenocarcinoma of the prostate

• Must have T1, T2 or T3a adenocarcinoma of the prostate

• Must be a candidate for radiation therapy. Hormone refractory patients excluded

• WHO/ECOG score of 0,1 or 2

Exclusion Criteria:

• NO evidence of urinary tract that would put the patient at risk in the opinion of the Investigator.

• Used the following treatments for prostate Cancer

*immunotherapy *chemotherapy *External Beam Radiation *brachytherapy *hormonal therapy *biological response modifiers

• Prior Prostate Surgery (excluding TUNA or TURP)

• Undergone Orchiectomy, adrenalectomy, hypophysectomy or be receiving any product which could alter the function of these organs

• Use of Investigational Drug, Biologic or device within five half-lives of its physiological action or three months prior to base line, whichever is longer

• Over the counter or alternative medical therapies which have estrogenic or anti-androgenic effect

• uncontrolled CHF within 6 months to baseline

• Myocardial Infarct, coronary vascular procedure or Clinically SignificantCardiovascualr Disease within 6 months of baseline Visit

• Venous thrombosis with in 6 Months of Screening

• Uncontrolled Hypertension defined as >170/100 or Symptomatic Hypotension within 3 months of Baseline

• Insulin dependant Diabetic Patients Must not administer in an anatomic region where they will receive Eligard.

• Drug or Alcohol Abuse 6 months prior to Baseline

• Other Serious Illness at the discretion of the Investigator

• Patients receiving anti-coagulant or anti-platlet medication must be on a stable dose for 3 months prior to Baseline

• Hypersensitivity to GnRH, GnRH agonists

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Eligard (TM)
Eligard (TM) 22.5 mg administered at baseline and Month 3

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Chesapeake Urology Research Associates	Sanofi-Synthelabo

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum Testosterone Recovery	To Evaluate the time to testosterone recovery, which is defined as a return to with in 90% of pretreatment level, after 6 months of neo-adjuvant treatment with Eligard 22.5mg with Radiation Therapy in patients with early prostate Cancer	6 mos
Secondary	Safety Assessments	Assess frequency and severity of spontaneously reported AE's Changes between baseline and testosterone recovery in serum testosterone and pre biopsy PSA clinical evidence of Prostate cancer changes between baseline and testosterone recovery in health questionnaire	6 months